Trial site

K2 Medical Research

Maitland, Florida 32751, United StatesNot linked to an institution yet

23running trials
13closed trials

The trials here

What the 36 trials at this site are about, from their registry records.

Conditions: Alzheimer disease23 trials
Depression5 trials
Obesity2 trials
Type 2 diabetes2 trials
Epilepsy1 trial
Fatty liver disease (MASLD/MASH)1 trial
Frontotemporal dementia1 trial
Heart failure1 trial
Osteoarthritis1 trial
Parkinson disease1 trial
Schizophrenia1 trial
Phase: Phase 316 trials
Phase 28 trials
Phase 16 trials
Phase 1/22 trials
Phase 2/32 trials
Status: Completed11 trials
Recruiting11 trials
Active, not recruiting6 trials
Not yet recruiting5 trials
Terminated2 trials
Enrolling by invitation1 trial
Lead sponsor: Eli Lilly and Company10 trials
Annovis Bio Inc.3 trials
Janssen Research & Development, LLC3 trials
Intra-Cellular Therapies, Inc.2 trials
Novo Nordisk A/S2 trials
and 16 more

Running trials

Not yet recruiting
An Open-label Long-term Safety Study of Buntanetap in Participants With AD
NCT07757204· Phase 2/3· Annovis Bio Inc.· Source
Contact: Gina Cedano
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
NCT07843459· Phase 1· Eli Lilly and Company· Source
Contact: Brandon Lenox (principal investigator)
Recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
NCT07787169· Phase 1· Eli Lilly and Company· Source
Contact: Brandon Lenox (principal investigator)
Recruiting
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119· Phase 3· Rapport Therapeutics Inc.· Source
Contact: Rapport Medical
Recruiting
A Study of LY3439539 in Participants With Alzheimer's Disease
NCT07598370· Phase 1· Eli Lilly and Company· Source
Contact: Shelia Baez-Torres (principal investigator)
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602· Phase 3· NewAmsterdam Pharma· Source
Recruiting
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
NCT07787182· Phase 1· Eli Lilly and Company· Source
Contact: Brandon Lenox (principal investigator)
Enrolling by invitation
Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)
NCT06605105· Phase 3· Cybin IRL Limited· Source
Active, not recruiting
53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee
NCT06865079· Phase 2· OrthoTrophix, Inc· Source
Active, not recruiting
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT06709014· Phase 3· Annovis Bio Inc.· Source
Recruiting
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768· Phase 1· Eli Lilly and Company· Source
Contact: Brandon Lenox (principal investigator)
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
NCT06651567· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
NCT06632444· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
NCT06584357· GAP Innovations, PBC· Source
Contact: Tiffany Kiako
Active, not recruiting
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027· Phase 3· Cerevance· Source
Recruiting
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06540833· Phase 2· Intra-Cellular Therapies, Inc.· Source
Recruiting
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
NCT06189963· Phase 1/2· NKGen Biotech, Inc.· Source
Contact: Adaliz Rodriguez
Active, not recruiting
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486· Phase 3· Eli Lilly and Company· Source
Recruiting
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688· Phase 3· Lantheus Biosciences Ltd.· Source
Contact: Audrey Perrotin, PhD
Active, not recruiting
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Alzheimer disease11 recruiting
Depression2 recruiting
Obesity2 recruiting
Epilepsy1 recruiting
Fatty liver disease (MASLD/MASH)1 recruiting
Heart failure1 recruiting
Schizophrenia1 recruiting

Closed trials

Completed
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012· Phase 2· Janssen Research & Development, LLC· Source
Terminated
Study of ASN51 in Adults With Early Alzheimer's Disease
NCT06677203· Phase 2· Asceneuron S.A.· Source
Completed
A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease
NCT06343636· Phase 1· Vigil Neuroscience, Inc.· Source
Completed
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
NCT05971940· Phase 3· Eli Lilly and Company· Source
Completed
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT05686044· Phase 2/3· Annovis Bio Inc.· Source
Completed
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532· Phase 3· Janssen Research & Development, LLC· Source
Completed
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder
NCT05593029· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731· Phase 3· Eli Lilly and Company· Source
Completed
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
NCT05364307· Global Alzheimer's Platform Foundation· Source
Terminated
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
NCT05026177· Phase 3· Cassava Sciences, Inc.· Source
Completed
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
NCT05063539· Phase 2· Eli Lilly and Company· Source
Completed
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
NCT04592874· Phase 2· Alector Inc.· Source
Completed
Gene Therapy for APOE4 Homozygote of Alzheimer's Disease
NCT03634007· Phase 1/2· Lexeo Therapeutics· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error